Managing Jaundice Neonatal

Required Documents

• Maternal blood type and antibody screen
• Infant blood type and direct antiglobulin test (DAT/Coombs)
• Serial bilirubin measurements with time stamps (TSB or TcB)
• Birth weight and current weight
• Feeding log (type of feeding, frequency, output)
• G6PD status (if known or if high-risk ethnicity)

TcB is acceptable for screening but if TcB is within 3 mg/dL of the phototherapy threshold, a confirmatory TSB must be obtained.

Step 1 — Bilirubin Measurement and Risk Zone Assignment (Bhutani Nomogram)

Pre-Discharge Bilirubin Assessment

• Obtain TSB or TcB on every newborn before discharge (universal screening per AAP 2022)
• Plot the result on the Bhutani hour-specific bilirubin nomogram
• Assign risk zone:

Rate of Rise

• Calculate bilirubin rate of rise if ≥ 2 values available
• Rate > 0.2 mg/dL/hour in first 24 hours is concerning for hemolysis
• Rate > 0.3 mg/dL/hour at any time warrants urgent evaluation

First 24 Hours

• Jaundice visible in the first 24 hours of life is ALWAYS pathologic until proven otherwise
• Obtain TSB immediately and evaluate for hemolytic disease (blood type incompatibility, G6PD deficiency, spherocytosis)

Step 2 — Neurotoxicity Risk Factor Assessment

The AAP 2022 guideline uses neurotoxicity risk factors to adjust phototherapy and exchange transfusion thresholds. Identify the presence of ANY of the following:

Neurotoxicity Hyperbilirubinemia Risk Factors

• Gestational age 35-37 weeks and 6 days (lower GA = higher risk)
• Albumin < 3.0 g/dL
• Isoimmune hemolytic disease (positive DAT — ABO or Rh incompatibility)
• G6PD deficiency
• Significant lethargy or sepsis
• Acidosis (pH < 7.15)
• Instability of clinical condition

Risk Category Assignment

Step 3 — Phototherapy Initiation

AAP 2022 Phototherapy Thresholds (Hour-Specific)

Thresholds vary by infant age in hours and risk category. Key representative values for term infants without risk factors:

Use the actual AAP 2022 phototherapy nomogram for precise thresholds at each hour of life — the above are approximate reference points.

Phototherapy Technical Standards

• Intensive phototherapy delivers ≥ 30 µW/cm²/nm in the 430-490 nm wavelength band
• Maximize skin surface area exposure (diaper only, no eye shields blocking forehead)
• Proper eye protection (opaque eye shields, check position frequently)
• Continue breastfeeding during phototherapy (supplement if intake is inadequate)
• Recheck TSB 4-6 hours after initiation; then every 6-12 hours during treatment
• Do NOT use sunlight exposure as a substitute for phototherapy

When to Escalate

• TSB rising despite phototherapy → verify equipment irradiance, increase skin exposure, consider double or triple lights
• TSB approaching exchange transfusion threshold → prepare for potential exchange; notify NICU/transport

Step 4 — Exchange Transfusion Thresholds

Indications for Exchange Transfusion

• TSB exceeds exchange transfusion threshold for age in hours and risk category (approximately 5 mg/dL above phototherapy threshold in most cases)
• TSB fails to decline by 1-2 mg/dL within 4-6 hours of intensive phototherapy and is approaching exchange threshold
• Signs of acute bilirubin encephalopathy (ABE) at ANY bilirubin level

Signs of Acute Bilirubin Encephalopathy (ABE)

Early phase:

• Lethargy, hypotonia, poor suck Advanced phase:
• Hypertonia (retrocollis, opisthotonos), high-pitched cry, fever
• Any neurologic sign attributable to bilirubin → EMERGENT exchange transfusion regardless of TSB level

Exchange Transfusion Protocol

• Double-volume exchange (160-180 mL/kg) replaces approximately 85% of circulating RBCs
• Reduces TSB by approximately 50%
• Requires NICU setting with continuous monitoring
• Complications: electrolyte disturbances (hypocalcemia, hyperkalemia), thrombocytopenia, NEC, line complications, cardiac arrhythmia

Step 5 — Discharge Planning and Follow-Up

Pre-Discharge Checklist

• Pre-discharge TSB or TcB plotted on Bhutani nomogram with risk zone assigned
• Risk factors documented (blood type, DAT, G6PD if applicable, GA)
• Feeding assessment: latch, frequency, urine/stool output, percent weight loss

Follow-Up Scheduling Based on Risk Zone and Age at Discharge

Phototherapy Discontinuation

• Discontinue when TSB drops 2-3 mg/dL below the phototherapy threshold for age
• Recheck TSB 12-24 hours after discontinuation (rebound occurs in ~10-15% of cases)
• Higher rebound risk with hemolytic disease and younger gestational age

Breastfeeding Support

• Do NOT discontinue breastfeeding for jaundice management
• Optimize breastfeeding: 8-12 feeds/day, lactation consultation, supplement with expressed breast milk or formula if intake is insufficient
• "Breastfeeding jaundice" (suboptimal intake) is managed by improving breastfeeding, not stopping it
• "Breast milk jaundice" (prolonged indirect hyperbilirubinemia after 1 week) rarely requires intervention; TSB > 20 mg/dL warrants evaluation but does not typically require cessation of breastfeeding

Checkpoint B — Jaundice Management Review

• TSB or TcB obtained with exact time stamp and infant age in hours
• Bilirubin plotted on Bhutani nomogram with risk zone documented
• Rate of rise calculated (if ≥ 2 values available)
• Neurotoxicity risk factors systematically assessed and documented
• Phototherapy threshold correctly identified for age and risk category
• If phototherapy initiated: irradiance verified, recheck interval set
• Exchange transfusion threshold identified; team aware if TSB approaching
• ABE signs assessed and documented (lethargy, tone, cry, feeding)
• Breastfeeding status assessed with plan for optimization
• Discharge follow-up scheduled per risk zone
• All [VERIFY] flags resolved or escalated

Quality Audit

Guidelines

• Follow AAP 2022 Clinical Practice Guideline for Management of Hyperbilirubinemia in Newborns ≥ 35 Weeks' Gestation (replaces 2004 guideline)
• Use Bhutani hour-specific bilirubin nomogram for pre-discharge risk stratification
• Use AAP 2022 hour-specific phototherapy and exchange transfusion threshold nomograms (separate from Bhutani prediction nomogram)
• G6PD deficiency: AAP recommends universal G6PD screening; if not available, screen high-risk populations (African, Mediterranean, Middle Eastern, Southeast Asian descent)
• TcB is valid for screening but confirm with TSB when within 3 mg/dL of threshold
• Phototherapy irradiance standard: ≥ 30 µW/cm²/nm (intensive) measured at infant skin level
• Do not interrupt breastfeeding for jaundice management — optimize feeding support
• ABE signs mandate emergent exchange transfusion at any TSB level
• Follow AAP safe discharge guidelines: no newborn should be discharged without a bilirubin assessment and follow-up plan
• This skill produces clinical documentation; it does not replace clinical judgment